2026 Global: 3D Bioprinting Market-Competitive Review (2032) report
Description
The 2026 Global: 3D Bioprinting Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for 3d bioprinting market by geography and historical trend. The scope of the report extends to sizing of the 3d bioprinting market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BICO (Cellink) is a global leader producing a broad portfolio of bioprinters, bioinks and cell-culture platforms for tissue engineering and drug discovery, with a strategy of product diversification and acquisitions to scale its research and commercial offerings. 3D Systems develops production-grade bioprinting systems, biomaterials and software and has spun out dedicated ventures to commercialize vascularized tissue models and regenerative implants, positioning itself across research and industrial manufacturing segments. Organovo (now VivoSim Labs/Organovo lineage) focuses on scaffold‑free, multicellular tissue models for toxicology and drug development and has shifted toward therapeutic tissue products and modular assay panels to support IND applications. Merck KGaA supplies life‑science reagents, bioinks and biofabrication consumables to bioprinting workflows and expands its distribution and service footprint globally to support researchers and manufacturers in the biofabrication ecosystem. CollPlant develops recombinant plant‑based collagen bioinks and regenerative‑medicine programs, collaborating with strategic partners to pursue complex organ scaffolds and commercial bioink supply chains for clinical and cosmetic applications. RegenHU designs and manufactures advanced extrusion and laser‑assisted bioprinting platforms aimed at regenerative‑medicine and drug‑discovery customers, emphasizing integrated hardware‑bioink solutions for complex tissue fabrication. Aspect Biosystems offers a proprietary microfluidic “Lab‑on‑a‑Printer” platform to produce vascularized, highly organized tissues for drug screening and has attracted significant venture capital to advance therapeutics toward the clinic. Cyfuse Biomedical provides unique scaffold‑free, Kenzan method bioprinters that assemble cellular spheroids into tissue constructs for regenerative and research uses, differentiating on scaffold‑less manufacturing and scalability. EnvisionTEC (now part of larger industrial groups) supplies high‑resolution bioprinting devices used across dental, medical and biofabrication markets and is noted for its robust stereolithography and DLP‑based systems that address precision tissue‑engineering needs. Poietis develops laser‑assisted bioprinting technologies that target precision placement of cells and biomaterials for skin and organotypic models, aiming at reproducible high‑resolution constructs for both R&D and translational applications.
BICO/Cellink, 3D Systems and Organovo represent companies with broad strategic footprints spanning instruments, materials and application development, while Merck and CollPlant anchor the materials and supply side with scalable bioink and reagent offerings that support commercial biomanufacturing. RegenHU, Aspect Biosystems, Cyfuse, EnvisionTEC and Poietis provide differentiated printing modalities—extrusion, microfluidic, scaffold‑free, stereolithography/DLP and laser‑assisted—that collectively address varying resolution, throughput and cell‑compatibility tradeoffs required by drug screening, disease modelling and regenerative‑therapy developers. Market analyses and industry reports consistently list these firms among the top players due to their product portfolios, strategic partnerships, capital raises and technology milestones that together drive adoption across academia, pharma and emerging clinical manufacturing use cases.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for 3d bioprinting market by geography and historical trend. The scope of the report extends to sizing of the 3d bioprinting market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BICO (Cellink) is a global leader producing a broad portfolio of bioprinters, bioinks and cell-culture platforms for tissue engineering and drug discovery, with a strategy of product diversification and acquisitions to scale its research and commercial offerings. 3D Systems develops production-grade bioprinting systems, biomaterials and software and has spun out dedicated ventures to commercialize vascularized tissue models and regenerative implants, positioning itself across research and industrial manufacturing segments. Organovo (now VivoSim Labs/Organovo lineage) focuses on scaffold‑free, multicellular tissue models for toxicology and drug development and has shifted toward therapeutic tissue products and modular assay panels to support IND applications. Merck KGaA supplies life‑science reagents, bioinks and biofabrication consumables to bioprinting workflows and expands its distribution and service footprint globally to support researchers and manufacturers in the biofabrication ecosystem. CollPlant develops recombinant plant‑based collagen bioinks and regenerative‑medicine programs, collaborating with strategic partners to pursue complex organ scaffolds and commercial bioink supply chains for clinical and cosmetic applications. RegenHU designs and manufactures advanced extrusion and laser‑assisted bioprinting platforms aimed at regenerative‑medicine and drug‑discovery customers, emphasizing integrated hardware‑bioink solutions for complex tissue fabrication. Aspect Biosystems offers a proprietary microfluidic “Lab‑on‑a‑Printer” platform to produce vascularized, highly organized tissues for drug screening and has attracted significant venture capital to advance therapeutics toward the clinic. Cyfuse Biomedical provides unique scaffold‑free, Kenzan method bioprinters that assemble cellular spheroids into tissue constructs for regenerative and research uses, differentiating on scaffold‑less manufacturing and scalability. EnvisionTEC (now part of larger industrial groups) supplies high‑resolution bioprinting devices used across dental, medical and biofabrication markets and is noted for its robust stereolithography and DLP‑based systems that address precision tissue‑engineering needs. Poietis develops laser‑assisted bioprinting technologies that target precision placement of cells and biomaterials for skin and organotypic models, aiming at reproducible high‑resolution constructs for both R&D and translational applications.
BICO/Cellink, 3D Systems and Organovo represent companies with broad strategic footprints spanning instruments, materials and application development, while Merck and CollPlant anchor the materials and supply side with scalable bioink and reagent offerings that support commercial biomanufacturing. RegenHU, Aspect Biosystems, Cyfuse, EnvisionTEC and Poietis provide differentiated printing modalities—extrusion, microfluidic, scaffold‑free, stereolithography/DLP and laser‑assisted—that collectively address varying resolution, throughput and cell‑compatibility tradeoffs required by drug screening, disease modelling and regenerative‑therapy developers. Market analyses and industry reports consistently list these firms among the top players due to their product portfolios, strategic partnerships, capital raises and technology milestones that together drive adoption across academia, pharma and emerging clinical manufacturing use cases.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.